RecruitingAdvanced Solid Tumors
A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.
Eligible age
18+ yrs
Accepts
All genders
Locations
2 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The study is a dose-escalation and dose-expansion study to evaluate the safety, tolerability, and pharmacokinetics of ASKG915 as a single agent or in combination with standard of care (SOC) in patients with selected types of advanced solid tumors.
Sponsor: AskGene Pharma, Inc.
You may qualify if…
- ✓ 1. Histologically or cytologically confirmed advanced malignant tumor that is refractory to or intolerant of all standard therapy or for which no standard therapy is available.
- ✓ 2. ECOG performance status of ≤ 2.
- ✓ 3. Life expectancy of ≥ 3 months.
- ✓ 4. The results of the laboratory tests must meet all criteria.
You may not qualify if…
- ✕ 1. Patients have received antitumor therapy during the first 4 weeks before study drug use.
- ✕ 2. Received a live attenuated vaccine within 4 weeks prior to C1D1.
- ✕ 3. Known cerebral parenchymal metastasis or meningeal metastasis.
- ✕ 4. History of serious cardiovascular or cerebrovascular diseases.
- ✕ 5. Active or recurrent autoimmune diseases.
- ✕ 6. History of ascites or pleural effusion requiring drainage.
- ✕ 7. Pregnant or lactating or planning to become pregnant at any time during the study, including the Follow-up Period.
Where it's recruiting
New York
New York
Pennsylvania
Pittsburgh
Source: ClinicalTrials.gov · NCT05867420 · last updated 2026-01-27